Genfit S.A. (EPA:GNFT – Get Free Report)’s share price dropped 0.8% during trading on Thursday . The company traded as low as €3.19 ($3.39) and last traded at €3.21 ($3.41). Approximately 36,724 shares traded hands during trading, The stock had previously closed at €3.24 ($3.44).
Genfit Stock Performance
The stock has a 50-day moving average price of €3.27 and a 200 day moving average price of €3.28.
About Genfit
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Further Reading
- Five stocks we like better than Genfit
- Learn Technical Analysis Skills to Master the Stock Market
- Hasbro’s Management Made All the Right Calls This Quarter
- How to Invest in Insurance Companies: A Guide
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
